MUMBAI: Girgaum’s well-known sweet establishment, Ganesh Bhandar, was served a ‘stop activity’ notice by the state Food and Drug Administration (FDA) following suspicions of certain items being misbranded and substandard. During investigation, it was revealed that the popular sweet shop was also operating without a licence. This move was part of the department’s festival season surveillance.
The owner Shantanu Ashok Patnaik’s outlets at CP Tank in Girgaum and Thakurdwar in Kalbadevi were raided by the FDA on Wednesday. The officials seized cashews worth over Rs 85,000 and kaju katli, a top-selling item, Shailesh Adhao, joint commissioner of FDA, said.
We also published the following articles recently
The owner Shantanu Ashok Patnaik’s outlets at CP Tank in Girgaum and Thakurdwar in Kalbadevi were raided by the FDA on Wednesday. The officials seized cashews worth over Rs 85,000 and kaju katli, a top-selling item, Shailesh Adhao, joint commissioner of FDA, said.
We also published the following articles recently
FDA serves stop activity notice on eatery at BKC
Burn – Bar and Kitchen in Mumbai has been served a stop activity notice by the state Food and Drug Administration (FDA) due to hygiene violations. The restaurant failed to meet licensing conditions, possessed expired goods, used synthetic food colour, and did not properly segregate vegetarian and non-vegetarian items. They also did not provide medical fitness records for their kitchen staff and water analysis reports. This is the 18th restaurant in the city to be temporarily shut down for hygiene standard violations since August.
Burn – Bar and Kitchen in Mumbai has been served a stop activity notice by the state Food and Drug Administration (FDA) due to hygiene violations. The restaurant failed to meet licensing conditions, possessed expired goods, used synthetic food colour, and did not properly segregate vegetarian and non-vegetarian items. They also did not provide medical fitness records for their kitchen staff and water analysis reports. This is the 18th restaurant in the city to be temporarily shut down for hygiene standard violations since August.
BKC restaurant served stop activity notice by Maharashtra FDA
The Burn-Bar and Kitchen in Mumbai has been served a stop activity notice by the state Food and Drug Administration (FDA) due to hygiene violations. The FDA discovered breaches of licensing conditions, expired goods, synthetic food colour, and a lack of segregation between vegetarian and non-vegetarian items. The restaurant failed to provide medical fitness records and water analysis reports. This is the 18th restaurant in the city to be temporarily shut down for hygiene violations since August. Additionally, a milk adulteration racket was busted in Vile Parle, with samples collected for further investigation.
The Burn-Bar and Kitchen in Mumbai has been served a stop activity notice by the state Food and Drug Administration (FDA) due to hygiene violations. The FDA discovered breaches of licensing conditions, expired goods, synthetic food colour, and a lack of segregation between vegetarian and non-vegetarian items. The restaurant failed to provide medical fitness records and water analysis reports. This is the 18th restaurant in the city to be temporarily shut down for hygiene violations since August. Additionally, a milk adulteration racket was busted in Vile Parle, with samples collected for further investigation.
US FDA approves Lilly weight-loss drug, will compete with Novo’s Wegovy
The US Food and Drug Administration has approved Eli Lilly’s drug for weight loss, allowing the company to enter the lucrative market. The drug, tirzepatide, will be sold under the brand name Zepbound and will be available in the US by the end of the year. It is approved for use by adults with a body mass index (BMI) of at least 30, or a BMI of 27 or more with another weight-related health issue. The drug’s most common side effects include nausea, diarrhea, hair loss, and gastroesophageal reflux disease.
The US Food and Drug Administration has approved Eli Lilly’s drug for weight loss, allowing the company to enter the lucrative market. The drug, tirzepatide, will be sold under the brand name Zepbound and will be available in the US by the end of the year. It is approved for use by adults with a body mass index (BMI) of at least 30, or a BMI of 27 or more with another weight-related health issue. The drug’s most common side effects include nausea, diarrhea, hair loss, and gastroesophageal reflux disease.
link